true
incid
viral
sepsi
particularli
pediatr
popul
remain
unknown
sinc
bacteri
sepsi
amen
treatment
presum
common
viral
test
frequent
foregon
acut
present
sepsi
howev
recent
studi
adult
patient
sepsi
show
viral
respiratori
pathogen
name
influenza
viru
human
metapneumoviru
coronaviru
respiratori
syncyti
viru
rsv
overlook
patient
multin
epidemiolog
studi
children
sever
sepsi
infecti
etiolog
proven
patient
approxim
onethird
viral
infect
frequent
site
infect
respiratori
tract
bloodstream
rhinoviru
rsv
adenoviru
commonli
isol
contrast
australia
new
zealand
sepsi
studi
group
identifi
pathogen
approxim
patient
sepsi
septic
shock
patient
onefifth
viral
etiolog
rsv
cytomegaloviru
cmv
epsteinbarr
viru
ebv
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
influenza
common
virus
identifi
studi
recent
ame
et
al
report
pediatr
patient
present
septic
shock
primari
viral
diseas
anoth
studi
neonat
sepsi
bacteri
etiolog
found
approxim
case
make
viral
infect
like
plausibl
caus
sepsi
patient
pediatr
intens
care
unit
picu
influenza
viru
lead
caus
viral
sepsi
cari
especi
high
mortal
rate
rsv
also
found
caus
sever
bronchiol
may
present
sepsi
especi
children
histori
prematur
birth
chronic
lung
diseas
congenit
heart
diseas
primari
immunodefici
sepsi
also
observ
neonat
hsv
human
parechoviru
hpev
enterovir
infect
patient
immunodefici
due
human
immunodefici
viru
hiv
infect
highli
suscept
viral
sepsi
depend
stage
diseas
access
respons
treatment
patient
common
viral
infect
observ
caus
sepsi
includ
rsv
influenza
parainfluenza
adenoviru
cmv
ebv
vzv
diarrheal
diseas
secondari
viral
infect
also
lead
sepsi
especi
develop
countri
although
rare
rotaviru
associ
sepsi
due
bacteri
coinfect
despit
sever
larg
studi
viral
sepsi
gener
ref
well
specif
virus
absenc
routin
viral
test
diagnost
evalu
sepsi
true
incid
viral
infect
caus
sepsi
remain
unclear
pathogenrecognit
receptor
prr
cellular
sensor
recogn
specif
molecular
structur
pathogen
tolllik
receptor
tlr
retino
acidinduc
genei
rigi
like
receptor
rlr
two
type
prr
involv
viral
sens
tlr
found
cell
surfac
within
endosom
monocyt
macrophag
dendrit
epitheli
endotheli
cell
encount
pathogenassoci
molecular
pattern
pamp
intracellular
recogn
singlestrand
ribonucl
acid
rna
virus
like
hpev
enterovirus
human
metapneumoviru
influenza
intracellular
recogn
doublestrand
ds
dna
virus
like
herp
virus
eg
ebv
adenoviru
cmv
recogn
dsrna
produc
intracellular
viral
replic
tlr
activ
culmin
myeloid
differenti
primari
respons
tollinterleukin
il
receptor
domaincontain
adapt
protein
induc
trif
activ
protein
turn
activ
nuclear
factor
kappalightchainenhanc
activ
b
cell
ifnregulatori
factor
ifr
mediat
cytokin
transcript
rlr
cytosol
innat
immun
sensor
viral
rna
three
member
rlr
identifi
rigi
melanoma
differenti
associ
factor
laboratori
genet
physiolog
rigi
recogn
dsrna
respons
differ
rna
virus
signal
product
proinflammatori
cytokin
ifn
cytokin
prolifer
instig
proinflammatori
cascad
result
complement
activ
neutrophil
chemotaxi
cytotox
cluster
differenti
cd
tcell
recruit
proteas
releas
leukocyt
endotheli
cell
particularli
trypsin
heparanas
trypsin
upregul
releas
vascular
endothelium
shown
cleav
circul
promatrix
metalloproteinas
prommp
releas
macrophag
form
activ
mmp
mmp
conjunct
heparanas
degrad
endotheli
glycocalyx
moreov
viral
particl
induc
reactiv
oxygen
speci
gener
circul
neutrophil
eosinophil
macrophag
injur
endotheli
glycocalyx
activ
cellsign
propag
positivefeedback
loop
result
endotheliopathi
endorgan
damag
system
viral
dissemin
appear
etiolog
viral
sepsi
exact
mechan
virus
normal
isol
respiratori
integumentari
epithelium
reach
bloodstream
known
howev
plausibl
viremia
occur
direct
invas
epitheli
cell
neuron
case
hsv
varicella
diseas
reach
surround
vasculatur
blood
viru
may
induc
endotheli
glycocalyx
degrad
activ
leukocyt
platelet
endotheli
cell
secret
mmp
heparanas
target
glycocalyx
compon
endotheli
glycocalyx
disrupt
expos
selectin
intracellular
adhes
molecul
make
avail
leukocyt
adhes
activ
glycocalyx
degrad
also
releas
heparan
sulfat
may
bind
activ
antithrombin
iii
expos
membranebound
glycoprotein
ibixv
complex
bind
circul
von
willebrand
factor
pselectin
platelet
precipit
coagulopathi
moreov
loss
integr
proteinrich
glycocalyx
alter
microvascular
fluid
equilibrium
vascular
lumen
subglycocalyx
increas
fluid
macromolecul
filtrat
endothelium
surround
interstitium
end
result
endotheli
glycocalyx
damag
proinflammatori
propag
vascular
leak
compromis
organ
function
circul
viral
particl
may
also
induc
endotheli
cell
structur
chang
lead
barrier
disrupt
vascular
leak
endotheli
cell
anchor
adheren
junction
compris
predominantli
vascular
endotheli
cadherin
attach
endotheli
cytoskeleton
betacatenin
human
endotheli
cell
pathogen
strain
hantaviru
appear
bind
cellular
surfac
therebi
promot
vecadherin
intern
adheren
junction
destabil
vecadherin
destabil
may
also
mediat
cellular
membran
receptor
receptor
activ
deriv
periendotheli
cell
activ
receptor
activ
cellsurviv
signal
cytoskelet
stabil
inflammatori
mediat
thrombin
reactiv
oxygen
speci
vegf
stimul
endotheli
cell
weibelpalad
bodi
exocytosi
releas
antagonist
act
autocrin
fashion
inhibit
signal
therebi
promot
rhoa
kinas
activ
vecadherin
destabil
mice
infect
pathogen
strain
influenza
viru
develop
acut
lung
injuri
rescu
agonist
vasculotid
suggest
receptor
integr
develop
endotheliopathi
viral
sepsi
exact
mechan
viru
employ
induc
endotheli
cell
dysfunct
clear
howev
typic
present
capillari
leak
viral
sepsi
suggest
common
pathway
endotheli
integr
compromis
viralinduc
host
cytotox
mediat
cytopath
effect
cellular
reprogram
andor
initi
host
immun
cytotox
respons
virus
take
util
host
intracellular
machineri
replic
deplet
host
cell
energi
store
transcript
potenti
furthermor
viralinfect
cell
may
activ
caspasedepend
apoptosi
virus
may
also
indirectli
promot
apoptosi
macrophag
reprogram
macrophag
infect
avian
influenza
shown
upregul
product
releas
tumor
necrosi
factor
tnf
relat
apoptosisinduc
ligand
trail
promot
tcell
apoptosi
though
effect
trail
cell
lineag
determin
plausibl
effect
seen
tcell
may
diffus
system
viral
dissemin
site
primari
infect
eg
human
metapneumoviru
respiratori
tract
hpev
gastrointestin
tract
may
occur
apoptot
mechan
wherebi
new
virion
releas
infect
local
endotheli
cell
caus
cellular
apoptosi
system
viral
spread
invas
pervas
viral
infect
like
dictat
cell
tropism
genet
determin
virul
virus
greater
cytopathogen
avian
influenza
like
caus
sepsi
immunocompet
host
virus
typic
minim
associ
cytopatholog
eg
rsv
parainfluenza
lastli
effector
host
immun
system
natur
killer
nk
cytotox
cell
complement
attack
destroy
viral
infect
host
cell
viral
pathogenesi
children
also
vari
accord
degre
host
immunocompet
gener
young
infant
significantli
reduc
tlr
express
antigenpres
cell
activ
nk
cell
respons
tcell
function
bcell
matur
complement
concentr
immatur
develop
immun
system
place
young
infant
significantli
higher
risk
sever
diseas
virus
would
typic
caus
minim
harm
older
children
adult
eg
hsv
hpev
enterovirus
cmv
similarli
children
congenit
acquir
immunodefici
suscept
viral
pathogen
specif
immunodefici
place
children
higher
risk
viral
sepsi
includ
nk
cell
defici
interferon
ifn
receptor
defici
defici
nuclear
factorkappa
b
essenti
modul
defici
sever
combin
immunodefici
sever
tcell
lymphopenia
digeorg
syndrom
agammaglobulinemia
hyperigm
syndrom
sever
rna
viral
infect
also
observ
patient
lossoffunct
mutat
ifn
induc
helicas
c
domain
gene
encod
rlr
moreov
children
receiv
immunomodulatori
immunosuppress
therapi
due
malign
transplant
autoimmun
diseas
suscept
viral
infect
reactiv
constitut
symptom
clinic
featur
viral
sepsi
frequent
indistinguish
bacteri
fungal
sepsi
present
symptom
sign
includ
fever
chill
rash
respiratori
distress
nausea
vomit
diarrhea
dysuria
confus
alter
mental
statu
none
symptom
pathognomon
sepsi
let
alon
viral
induc
sepsi
moreov
classic
featur
system
inflamm
might
seen
everi
individu
especi
immunocompromis
children
fever
one
common
symptom
seen
septic
children
attribut
pyrogen
activ
ifn
observ
substanc
increas
prostaglandin
synthesi
hypothalamu
result
elev
host
central
nervou
system
core
temperatur
setpoint
regul
preoptic
dorsomedi
hypothalam
nuclei
hypothermia
hand
less
frequent
specif
indic
sepsi
may
predict
ill
sever
death
especi
younger
children
chronic
debilit
patient
injuri
vascular
endothelium
may
result
broad
array
fail
organ
manifest
confus
nausea
vomit
diarrhea
oliguria
coagulopathi
myriad
cardiopulmonari
manifest
rang
mild
tachypnea
tachycardia
acut
respiratori
distress
syndrom
shock
seen
present
symptom
usual
depend
type
viru
clinic
present
patient
respiratori
viral
infect
rang
complet
asymptomat
sever
respiratori
distress
due
pneumonia
diarrheal
ill
observ
patient
infect
rotaviru
noroviru
enteroviru
adenoviru
vzv
hsv
infect
may
present
vesicular
rash
children
hsv
arboviru
infect
may
confus
alter
mental
statu
seizur
enceph
elev
transaminas
common
hsv
enterovir
infect
may
complic
hepat
coagulopathi
enceph
neonat
hpev
infect
mimic
enterovir
infect
initi
present
often
patient
present
fever
rash
irrit
feed
intoler
seizur
develop
sepsi
like
ill
enceph
patient
acut
hiv
infect
often
flulik
symptom
fever
headach
rash
usual
resolv
spontan
patient
soon
enter
phase
clinic
latenc
develop
acquir
immunodefici
syndrom
usual
herald
acquisit
opportunist
infect
type
sepsi
virusinduc
sepsi
requir
high
index
suspicion
especi
young
children
chronic
medic
condit
neonat
young
infant
higher
risk
sepsi
hsv
hpev
enteroviru
hsv
usual
acquir
perinat
mother
genit
herp
mother
primari
herp
like
transmit
infect
compar
recurr
nonprimari
herp
nielsen
et
al
report
second
born
children
higher
risk
infect
firstborn
seizur
drowsi
lethargi
absenc
oral
lesion
associ
sever
enterovir
infect
children
rsv
infect
comorbid
condit
report
increas
risk
sever
infect
includ
histori
prematur
congenit
heart
diseas
chronic
lung
diseas
immunodefici
recent
studi
eggleston
et
al
found
patient
metapneumoviru
infect
like
older
congenit
heart
diseas
compar
rsv
infect
patient
contrast
asthmat
prematur
infant
higher
risk
rhinoviru
infect
final
predispos
condit
sever
pediatr
influenza
infect
includ
age
less
year
asthma
cardiac
renal
hepat
hematolog
neurolog
neuromuscular
condit
longterm
aspirin
therapi
immunosuppress
therapi
resid
chronic
care
facil
risk
mothertochild
perinat
hiv
transmiss
higher
mother
count
lower
infant
receiv
antiretrovir
prophylaxi
patient
condit
present
sepsi
diagnost
viral
test
appropri
empir
antivir
treatment
strongli
consid
accord
individu
risk
factor
secondari
bacteri
infect
commonli
associ
respiratori
viral
infect
winter
outbreak
streptococcu
pneumonia
pneumonia
develop
otherwis
healthi
children
preced
influenza
viral
ill
influenza
pandem
one
third
critic
ill
children
afflict
influenza
diagnos
concurr
bacteri
infect
studi
lead
three
bacteri
coinfect
staphylococcu
aureu
pseudomona
spp
haemophilu
influenza
children
hospit
rsv
haemophilu
influenza
streptococcu
pneumonia
common
organ
isol
develop
bacteremia
secondari
bacteri
infect
may
exacerb
innat
immun
dysfunct
convey
substanti
increas
risk
wors
outcom
howev
date
mechan
underli
bacteri
synerg
increas
suscept
secondari
bacteri
infect
set
preced
respiratori
viral
infect
remain
unclear
gener
phenomenon
appear
involv
impair
respiratori
epitheli
innat
immun
system
defens
viral
destruct
airway
epithelium
affect
mucociliari
clearanc
allow
bacteri
attach
mucin
eventu
colon
respiratori
tract
addit
viralinduc
upregul
may
lead
dysregul
host
tcell
respons
decreas
neutrophil
chemotaxi
impair
macrophag
phagocytosi
increas
host
suscept
secondari
bacteri
pathogen
upregul
surfac
plateletactiv
factor
receptor
epitheli
cell
leukocyt
proinflammatori
cytokin
may
also
increas
adhes
invas
certain
virul
pneumococc
strain
rotaviru
infect
also
associ
secondari
bacteri
infect
although
exact
mechan
lead
sepsi
organ
dysfunct
unknown
lead
hypothesi
entail
transloc
bacteria
endotoxin
damag
intestin
epithelium
splanchnic
circul
system
increas
product
nitric
oxid
circul
proinflammatori
cytokin
like
tnf
high
mobil
group
box
protein
result
sequenti
organ
failur
hiv
infect
lead
apoptosi
tlymphocyt
defect
b
lymphocyt
function
decreas
product
immunoglobulin
decreas
nk
cell
activ
lead
increas
risk
secondari
bacteri
infect
also
increas
suscept
virus
intracellular
organ
mycobacteria
pneumocysti
jiroveci
similar
bacteri
coinfect
critic
ill
children
simultan
infect
multipl
virus
cours
ill
patient
viral
coinfect
depend
virusviru
interact
variou
mechan
diseas
virul
viral
coinfect
propos
includ
viral
gene
interact
immunolog
interact
alter
host
environ
even
though
clinic
signific
interact
unknown
studi
rhedin
et
al
report
increas
risk
sever
respiratori
diseas
patient
viral
coinfect
compar
singl
viral
infect
approxim
patient
viral
coinfect
rsv
bocaviru
adenoviru
common
virus
associ
coinfect
anoth
studi
perform
canada
patient
respiratori
viral
infect
approxim
patient
viral
coinfect
differ
risk
hospit
sever
ill
patient
singl
viral
infect
viral
coinfect
anoth
studi
done
greec
reveal
much
higher
viral
coinfect
rate
common
coinfect
rsv
influenza
rhinoviru
parainfluenza
virus
increas
risk
hospit
observ
patient
viral
coinfect
howev
systemat
review
metaanalys
children
viral
coinfect
shown
associ
increas
clinic
sever
patient
infect
hiv
high
risk
secondari
viral
infect
cmv
hsv
respiratori
virus
like
rsv
influenza
metapneumoviru
diagnosi
viral
sepsi
typic
one
exclus
bacteri
sepsi
whether
primari
secondari
usual
higher
initi
concern
failur
recogn
diagnosi
promptli
administ
system
antibiot
lethal
consequ
unfortun
current
state
limit
antivir
therapi
even
prompt
recognit
treatment
viral
sepsi
may
quickli
improv
patient
clinic
cours
nonetheless
earli
definit
diagnosi
primari
viral
septic
process
may
inform
treatment
decisionmak
help
limit
unnecessari
system
antibiot
administr
symptomat
critic
ill
children
identif
viral
etiolog
play
import
role
manag
impact
outcom
patient
current
standard
approach
viral
diagnost
test
pointofcar
poc
antigenbas
test
rel
inexpens
provid
rapid
detect
common
respiratori
virus
nasopharyng
swab
rsv
common
strain
human
influenza
howev
poc
test
may
lack
sensit
need
determin
etiolog
lifethreaten
sepsi
direct
fluoresc
antibodi
dfa
test
may
provid
better
specif
broader
rang
viral
strain
detect
poc
test
test
depend
collect
suffici
number
epitheli
cell
adequ
viral
detect
cell
cultur
tradit
goldstandard
viral
diagnos
includ
hsv
howev
long
turnaround
time
result
significantli
limit
util
expedi
diagnosi
commerci
laboratorydevelop
nucleic
acid
amplif
test
naat
eg
polymeras
chain
reaction
pcr
revers
transcriptionloopmedi
isotherm
amplif
may
provid
greater
sensit
specif
poc
dfa
test
requir
sophist
equip
special
train
laboratori
staff
complet
naat
ad
benefit
highli
multiplex
new
commerci
avail
technolog
like
multiplex
pcr
unfortun
use
naat
limit
high
cost
delay
result
inabl
distinguish
viral
nucleic
acid
live
virus
ultim
method
avail
time
viral
detect
limit
techniqu
sampl
collect
institut
resourc
avail
sever
limit
current
diagnost
test
caus
virus
worth
note
result
viral
test
alway
need
interpret
caution
instanc
although
type
enteroviru
hpev
detect
routin
enteroviru
pcr
assay
hpevspecif
pcr
requir
detect
viru
respiratori
csf
stool
sampl
infect
children
consid
part
workup
neonat
young
children
present
sepsi
clinic
util
viral
respiratori
pcr
panel
also
limit
high
rate
posit
detect
without
clinic
correl
detect
viru
patient
sepsi
necessarili
indic
causat
studi
shown
respiratori
viru
detect
one
third
asymptomat
children
viral
pcr
test
particularli
difficult
interpret
due
high
sensit
viral
nucleic
acid
make
challeng
clinician
distinguish
activ
viral
diseas
viral
nucleic
acid
live
viral
carriag
posit
test
could
result
asymptomat
colon
prolong
viral
shed
viral
coinfect
studi
rhedin
et
al
compar
pcr
result
symptomat
asymptomat
patient
rsv
metapneumoviru
parainfluenza
virus
significantli
higher
detect
rate
children
acut
respiratori
infect
suggest
causat
howev
virus
enteroviru
coronaviru
bocaviru
rhinoviru
adenoviru
equal
high
detect
rate
asymptomat
children
posit
viral
detect
asymptomat
children
import
clinician
consid
big
pictur
factor
pertin
inform
may
indic
activ
ongo
bacteri
infect
discontinu
antibacteri
agent
base
viral
assay
use
serum
biomark
see
section
whole
blood
gene
express
analysi
may
serv
crucial
role
set
discern
viral
bacteri
sepsi
face
septic
child
unusu
sepsi
present
respond
usual
therapi
persist
neg
diagnost
evalu
viral
etiolog
must
consid
consult
infecti
diseas
expert
recommend
sever
serum
biomark
includ
lactat
creactiv
protein
crp
procalcitonin
pct
use
guid
manag
sepsi
import
part
earli
goal
direct
therapi
pct
commonli
use
icu
set
earli
determin
likelihood
bacteri
etiolog
sepsi
guid
antimicrobi
durat
serum
pct
shown
elev
bacteri
infect
superior
crp
assess
sever
cours
diseas
howev
mean
sensit
pct
biomark
sepsi
remain
low
specif
unfortun
gener
biomark
nonspecif
distinguish
bacteri
vs
viral
infect
recent
year
sever
viralspecif
biomark
identifi
mani
transcript
signatur
design
distinguish
viral
infect
bacteri
infect
well
noninfecti
condit
zaa
et
al
identifi
signatur
discrimin
symptomat
influenza
ainfect
subject
healthi
bacteriallyinfect
subject
recent
studi
herberg
et
al
rna
signatur
show
promis
result
abil
distinguish
bacteri
viral
infect
demonstr
express
increas
patient
viral
infect
wherea
express
increas
patient
bacteri
infect
anoth
recent
studi
identifi
fourgen
express
signatur
whole
blood
distinguish
viral
infect
etiolog
human
myxoviru
resist
protein
mxa
import
intermedi
product
ifnmedi
antivir
respons
varieti
virus
serum
mxa
level
significantli
higher
patient
viral
infect
compar
bacteri
infect
pediatr
popul
thu
may
addit
use
biomark
discrimin
viral
bacteri
ill
pauciti
data
regard
treatment
manag
viral
infect
support
care
current
mainstay
therapi
viral
infect
particularli
respiratori
virus
though
broadspectrum
antibiot
therapi
may
prudent
bacteri
sourc
sepsi
definit
ruledout
sustain
antibiot
treatment
role
manag
viral
sepsi
except
case
bacteri
coinfect
mani
viral
infect
prevent
use
hand
hygien
environment
decontamin
use
person
protect
equip
elimin
secondhand
smoke
isol
infect
children
addit
protect
confer
administ
vaccin
common
communic
virus
prevent
strategi
particular
import
highrisk
patient
scope
avail
vaccin
antivir
therapi
remain
rather
limit
develop
novel
vaccin
treatment
critic
rsv
infect
manag
current
limit
passiv
immun
atrisk
infant
palivizumab
rsvspecif
monoclon
antibodi
food
drug
administr
fda
approv
prevent
infect
highrisk
infant
rsv
season
american
academi
pediatr
issu
clear
recommend
palivizumab
use
state
administ
monthli
inject
rsv
season
children
born
less
week
day
gestat
less
month
age
children
congenit
heart
diseas
chronic
lung
diseas
studi
shown
variabl
efficaci
palivizumab
reduct
rsv
hospit
rate
approxim
current
aerosol
ribavirin
fdaapprov
treatment
avail
manag
rsv
infect
though
use
remain
controversi
date
rsv
vaccin
antivir
therapi
remain
activ
area
investig
random
control
trial
perform
adult
patient
rsv
infect
compar
rsv
entri
inhibitor
placebo
demonstr
decreas
viral
load
clinic
sever
infect
patient
treat
similar
fusion
inhibitor
demonstr
efficaci
vitro
undergo
phase
ii
clinic
trial
infant
hospit
rsv
clinicaltrialsgov
registr
use
rsv
polymeras
inhibitor
similarli
shown
reduc
viral
load
rapidli
clear
rsv
improv
sever
diseas
adult
rsv
infect
lipidbas
nanoparticul
system
contain
smallinterf
rna
sirna
demonstr
promis
antivir
effect
rsv
lung
transplant
patient
target
mrna
rsv
nucleocapsid
protein
therebi
limit
viral
replic
howev
novel
treatment
undergon
appropri
clinic
trial
pediatr
medic
commun
must
continu
wait
effect
rsv
antivir
therapi
unlik
rsv
season
vaccin
sever
antivir
therapi
avail
treat
influenza
viral
infect
season
influenza
vaccin
demonstr
reason
efficaci
attenu
influenza
b
viral
diseas
current
two
form
influenza
vaccin
avail
use
children
live
attenu
vaccin
form
nasal
spray
inactiv
vaccin
inject
form
antivir
agent
use
treatment
postexposur
prophylaxi
influenza
infect
includ
neuraminidas
inhibitor
oseltamivir
zanamivir
adamantan
amantadin
rimantadin
oseltamivir
commonli
use
medic
due
high
preval
adamantan
resist
oseltamivir
shown
benefici
toler
children
influenza
receiv
within
first
h
ill
howev
case
sever
infect
initi
oseltamivir
beyond
h
symptom
onset
may
still
provid
benefit
nanotechnologybas
vaccin
also
develop
influenza
viru
inflexalr
v
influvacr
two
virosom
vaccin
shown
efficaci
influenza
infect
anoth
nanotherapeut
agent
sirna
develop
design
inhibit
conserv
region
strain
influenza
viru
prevent
viral
replic
nanotrap
sialylneolactontetraos
c
lstc
bear
liposom
decoy
bind
hemagglutinin
influenza
viru
prevent
viral
spread
vitro
demonstr
potenti
shown
effect
influenza
viru
influenza
polymeras
inhibitor
favipiravir
demonstr
signific
attenu
influenza
viru
activ
interestingli
higher
concentr
also
shown
effect
polioviru
rhinoviru
rsv
agent
investig
includ
longact
neuraminidas
inhibitor
attach
inhibitor
anim
studi
also
shown
promis
result
combin
therapi
variou
immunomodulatori
agent
also
posit
temper
dysregul
host
inflammatori
respons
sever
influenza
includ
inhibitor
doxycyclin
glucocorticoid
macrolid
peroxisom
proliferatoractiv
receptor
agonist
gemfibrozil
receptor
activ
vasculotid
studi
need
determin
efficaci
treatment
human
influenza
infect
pleconaril
oral
administ
viral
capsid
inhibitor
shown
effect
picornavirus
especi
enterovirus
rhinovirus
abzug
et
al
report
greater
surviv
patient
neonat
enterovir
sepsi
receiv
pleconaril
similarli
patient
rhinoviru
infect
treat
pleconaril
shorter
durat
symptom
depend
suscept
viru
medic
antivir
activ
observ
pleconaril
hpev
intraven
immunoglobulin
shown
potenti
benefit
manag
enterovir
infect
prevent
neonat
hsv
infect
elus
neonat
hsv
diseas
often
occur
transmiss
asymptomat
women
primari
hsv
infect
case
activ
matern
genit
herp
cesarean
section
decreas
incid
neonat
hsv
infect
especi
perform
within
h
ruptur
membran
subunit
hsv
vaccin
shown
promis
result
prevent
genit
herp
current
phase
iii
trial
although
routin
recommend
antivir
prophylaxi
acyclovir
late
pregnanc
demonstr
decreas
viral
shed
lead
reduct
cesarean
rate
recurr
herp
patient
sever
neonat
hsv
infect
dissemin
diseas
cn
infect
treat
intraven
acyclovir
day
viral
sepsi
may
occur
hivinfect
children
due
opportunist
secondari
viral
infect
increas
use
highli
activ
antiretrovir
therapi
haart
significantli
improv
surviv
hiv
infect
children
decreas
progress
acquir
immunodefici
syndrom
aid
therebi
maintain
host
immunocompet
protect
develop
viral
sepsi
howev
haart
associ
potenti
deleteri
sequela
make
time
therapi
controversi
patient
activ
sepsi
extens
studi
done
character
effect
viral
sepsi
outcom
recent
studi
hon
et
al
found
differ
mortal
patient
without
viral
infect
admit
picu
shi
et
al
perform
systemat
review
rsv
infect
estim
case
fatal
rate
children
rsv
infect
around
month
age
month
age
develop
countri
case
fatal
rate
higher
incom
countri
significantli
lower
month
month
anoth
studi
highest
mortal
rsv
infect
seen
mean
age
month
three
quarter
case
associ
comorbid
condit
season
influenza
epidem
variou
pandem
histor
led
signific
morbid
mortal
past
either
due
exacerb
underli
condit
due
secondari
bacteri
infect
mortal
influenza
vari
season
predomin
influenza
strain
effect
influenza
vaccin
season
first
year
pandem
global
mortal
children
age
year
estim
high
case
major
death
occur
southeast
asia
africa
pediatr
adult
patient
pandem
rapid
progress
respiratori
failur
requir
prolong
mechan
ventil
vasopressor
support
variou
extrapulmonari
complic
secondari
influenza
sepsi
report
literatur
includ
limit
renal
failur
rhabdomyolysi
encephalopathi
myocard
multiorgan
failur
complic
also
lead
poorer
outcom
sepsi
hpev
lead
signific
morbid
neonat
young
children
although
infect
selflimit
longterm
neurolog
deficit
learn
disabl
development
delay
paralysi
epilepsi
observ
patient
hpev
infect
also
associ
enceph
hepat
coagulopathi
addit
rare
complic
also
observ
patient
includ
necrot
enterocol
myocard
myositi
hemolyt
urem
syndrom
rey
syndrom
enterovir
infect
lead
similar
complic
longterm
neurolog
deficit
hepat
cardiac
dysfunct
also
observ
patient
hsv
infect
neurolog
complic
development
delay
seizur
observ
infect
neonat
mortal
system
hsv
infect
usual
due
sever
coagulopathi
hepat
pneumon
multicent
studi
spaeder
et
al
observ
mortal
rate
patient
sever
metapneumoviru
infect
increas
mortal
metapneumoviru
infect
observ
children
chronic
medic
condit
femal
gender
patient
acquir
infect
hospit
similarli
rsv
parainfluenza
influenza
infect
acquir
hospit
associ
increas
mortal
rotaviru
infect
lead
extraintestin
complic
like
seizur
meningoenceph
hiv
patient
likelihood
progress
aid
mortal
impact
time
acquisit
hiv
viral
load
count
time
haart
initi
approxim
mortal
observ
develop
countri
limit
access
haart
complic
lead
increas
morbid
mortal
patient
includ
sever
cmv
infect
encephalopathi
recurr
lifethreaten
bacteri
infect
tuberculosi
pneumocysti
infect
endorgan
failur
major
contributor
mortal
sepsi
septic
shock
includ
virusinduc
sepsi
complic
acut
respiratori
distress
syndrom
dissemin
intravascular
coagul
acut
renal
injuri
often
lead
wors
prognosi
develop
countri
often
disproportion
higher
mortal
patient
viral
infect
like
due
delay
diagnosi
treatment
risk
sever
sepsi
also
relat
site
infect
endocard
cn
infect
associ
mortal
high
besid
site
infect
type
viru
also
determin
risk
mortal
exampl
mening
hpev
common
caus
sepsi
neonat
young
children
consequ
mortal
low
patient
associ
sever
diseas
moreov
extent
system
involv
predict
develop
multipl
organ
failur
thu
mortal
sepsi
relat
mortal
report
viral
infect
includ
dengu
fever
howev
studi
necessari
order
estim
burden
viral
sepsi
outcom
includ
morbid
mortal
health
care
relat
cost
although
incid
viralinduc
sepsi
precis
known
suspect
common
may
repres
import
subset
children
cultureneg
sepsi
therefor
critic
clinician
suspect
test
viral
infect
children
cultureneg
sepsi
appropri
infect
contain
measur
institut
time
fashion
interest
earli
identif
children
viral
infect
amen
treatment
consider
especi
urgent
highrisk
children
born
prematur
congenit
heart
diseas
chronic
lung
diseas
immunodefici
appropri
diagnosi
viral
sepsi
may
provid
clinician
ad
confid
limit
durat
empir
antibacteri
exposur
children
sepsi
therefor
may
help
fight
antibioticresist
bacteria
studi
need
identifi
novel
viralspecif
biomark
therapeut
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
